Related Experiment Video
Updated: Feb 7, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
Raj K Kurupati1, Xiangyang Zhou1, Zhiquan Xiang1
1The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.
Abstract:
Human immunotherapy with checkpoint blockades has achieved significant breakthroughs in recent years. In this study, a checkpoint blockade vaccine for canine melanoma was tested for safety and immunogenicity. Five healthy adult dogs received a mixture of three replication-defective chimpanzee-derived adenoviral vectors, one expressing mouse fibroblast-associated protein (mFAP) and the others expressing canine melanoma-associated antigens Trp-1 or Trp-2 fused into Herpes Simplex-1 glycoprotein D, a checkpoint inhibitor of herpes virus entry mediator (HVEM) pathways. The vaccine mixture was shown to be well tolerated and increased frequencies of canineTrp-1-specific activated CD8+ and CD4+ T cells secreting interferon-(IFN)-γ, tumor necrosis factor (TNF)-α, or interleukin (IL)-2 alone or in combinations in four and five out of five dogs, respectively. To avoid excessive bleeds, responses to cTrp-2 were not analyzed. All dogs responded with increased frequencies of mFAP-specific activated CD8+ and CD4+ T cells. The results of this safety/immunogenicity trial invite further testing of this checkpoint blockade vaccine combination in dogs with melanoma.
Insights
This canine melanoma vaccine, using adenoviral vectors, showed safety and boosted T cell responses against melanoma antigens. Further testing is recommended for this promising cancer immunotherapy.
Area of Science:
- Veterinary Oncology
- Immunotherapy
- Cancer Vaccines
Background:
- Checkpoint blockade immunotherapy has revolutionized human cancer treatment.
- Canine melanoma represents a significant challenge in veterinary oncology.
- Developing effective and safe cancer vaccines for dogs is a critical need.
Purpose of the Study:
- To evaluate the safety and immunogenicity of a novel checkpoint blockade vaccine for canine melanoma.
- To assess the vaccine's ability to elicit T cell responses against melanoma-associated antigens.
Main Methods:
- Five healthy adult dogs were vaccinated with a mixture of three replication-defective adenoviral vectors.
- Vectors expressed mouse fibroblast-associated protein (mFAP) and canine melanoma antigens Trp-1 and Trp-2.
- Immune responses were measured by analyzing activated CD8+ and CD4+ T cells secreting cytokines like interferon-gamma (IFN-γ).
Main Results:
- The vaccine was well-tolerated in all dogs.
- Increased frequencies of canine Trp-1-specific activated T cells (CD8+ and CD4+) were observed in 4/5 dogs.
- All dogs showed increased mFAP-specific activated T cells, indicating successful immune stimulation.
Conclusions:
- The checkpoint blockade vaccine demonstrated a favorable safety profile and induced significant T cell immunogenicity in healthy dogs.
- These findings support further investigation of this vaccine combination for treating canine melanoma.
- This study paves the way for novel immunotherapeutic strategies in canine cancer treatment.
Related Concept Videos
Vaccinations
Neuromuscular Junction And Blockade
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Survey Safety
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Household Wiring And Electrical Safety

